Glaukos (NYSE:GKOS) Price Target Raised to $152.00

Glaukos (NYSE:GKOS) had its price objective raised by Truist Financial from $145.00 to $152.00 in a research note published on Monday, Benzinga reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

GKOS has been the topic of a number of other research reports. Stifel Nicolaus boosted their target price on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Piper Sandler boosted their price objective on Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Wells Fargo & Company raised their target price on Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a research report on Friday, August 30th. Finally, BTIG Research increased their price target on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $130.45.

Glaukos Stock Up 0.7 %

Shares of NYSE GKOS opened at $129.11 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67. The stock has a market capitalization of $6.50 billion, a PE ratio of -44.88 and a beta of 1.02. Glaukos has a one year low of $59.22 and a one year high of $136.60. The business’s fifty day moving average price is $127.91 and its 200-day moving average price is $116.55.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). The business had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company’s revenue was up 19.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.55) earnings per share. On average, equities research analysts anticipate that Glaukos will post -2.18 EPS for the current year.

Insider Activity

In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares of the company’s stock, valued at $3,614,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the transaction, the director now directly owns 30,119 shares in the company, valued at $3,614,280. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,250 shares of company stock worth $4,825,873. 6.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Glaukos

Institutional investors have recently bought and sold shares of the stock. Trust Point Inc. raised its holdings in Glaukos by 3.5% during the 3rd quarter. Trust Point Inc. now owns 11,343 shares of the medical instruments supplier’s stock valued at $1,478,000 after buying an additional 386 shares during the last quarter. Creative Planning raised its stake in shares of Glaukos by 64.1% during the third quarter. Creative Planning now owns 12,643 shares of the medical instruments supplier’s stock valued at $1,647,000 after acquiring an additional 4,937 shares during the last quarter. Procyon Advisors LLC purchased a new stake in shares of Glaukos during the third quarter worth about $210,000. Exchange Traded Concepts LLC bought a new stake in shares of Glaukos in the third quarter worth about $755,000. Finally, Inspire Investing LLC increased its holdings in Glaukos by 6.9% during the 3rd quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock valued at $416,000 after purchasing an additional 206 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.